Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will be fundamental to help the world in rethinking what's possible with vaccines.
Vaxxas' approach which has been validated in human clinical studies can enhance the efficiency and effectiveness of a vaccine's immune response. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain".
Vaxxas is targeting initial applications in infectious disease and oncology and has forged collaborations with leading global organizations in vaccine commercialization, including Merck/MSD, the United States Biomedical Advanced Research and Development Authority (BARDA), the World Health Organization (WHO), and the Bill and Melinda Gates Foundation.
David L. Hoey
President and CEO
Chief Business Officer and General Counsel
Angus Forster, Ph.D.
Chief Technology Officer
Scott Fry, Ph.D.
Chief Operating Officer
Dr Rochelle Chaiken
Chief Medical Officer
Chief Financial Officer
Senior Vice President Vaccine Alliances
Senior Vice President Advanced Technology
Megan Polidano, Ph.D.
Head of Clinical & Regulatory Affairs
Head of Manufacturing and Operational Excellence
Deborah Pascoe, Ph.D.
Head of Early-Stage & Preclinical R&D
Andrew Robertson, Ph.D.
Head of Vaccine Project Management
Sarika Namjoshi, Ph.D.
Head of Formulation & Analytical
Romulo De Macedo
Head of Medical Device and Process Development
Senior Vice President of Quality
Dr Ludovic Bonnet
Head of Technical Performance Improvement
Head of People & Performance
Board Of Directors
Dr. Paul Kelly is a Founder and Managing Partner of OneVentures and serves on the investment committee of OneVentures' three main Funds, chairing the Healthcare Fund III Investment Committee, and leads the healthcare and biotechnology practice across the firm. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of BiVACOR, Clinical Genomics and Prota Therapeutics.
Paul is an Australian physician and serial biotechnology entrepreneur with over 30 years' experience in developing and commercializing biomedical innovations in the United States, Europe, United Kingdom and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, with a record of achievement in transforming ideas, technologies and products into sustainable successful businesses and delivering strong returns for shareholders and investors as a founder and CEO.
Paul joined the OneVentures team in 2009, as a co-founder of OneVentures' first fund in 2010, after spending 15 years in the UK and USA (mostly in Boston, MA). Paul served as CEO of Gemini Genomics (Nasdaq:GMNI), one of the world's first clinical genomics companies, which he co-founded in 1995 to discover and commercialize novel gene-based diagnostic and therapeutic targets. In 2001, Paul led the company's successful merger with Sequenom (Nasdaq:SQNM). Paul then continued in the US working with local biotech and med-tech entrepreneurs and co-founded Agamatrix, now a leading bio-sensing medical device company with operations across the US and South East Asia, and Atomera (Nasdaq ATMR). He then served as President and CEO of Orchid Cellmark (Nasdaq:ORCH) at that time the world's leading provider of genetic testing services in both the UK and US.
Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specializing in endocrinology at St Vincent's Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute of Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.
He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Paul is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Hons), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians. He also serves on the Board of Directors of the Garvan Institute of Medical Research. Paul is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Hons), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians.
Dr. Manon M.J. Cox, MBA founded NextWaveBio early 2018 initially providing scientific and strategic direction to various biopharmaceutical companies. NextWaveBio's mission is to bridge the gap between preclinical and clinical development by offering infrastructure and education around quality systems required for clinical development and manufacturing.
Prior to that Dr. Cox led the development of Flublok®, the only FDA approved recombinant influenza vaccine at Protein Sciences Corporation where she served as President and Chief Executive Officer since April 2010 and Director since 2008. She joined Protein Sciences in 1998 as Director of Business Development and became Chief Operating Officer in 2003.
Previously Manon was with Gist-brocades, a large Dutch company specialized in fermentation, where she held various management positions during her 10 year tenure, most recently in New Business Development and before that in Production and Research and Development. Prior to joining Gist-brocades, she worked as a Molecular Biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam. She serves on the Board of Trustees of St. Joseph University (West Hartford, CT), the Board of the Netherland-America Foundation and its Education & Nominating Committees, the Board of the International Society for Vaccines (ISV), and the Scientific Advisory Board of Epivax Therapeutics.
Dr. Cox has received many honors and awards recognizing her stature as a leader in innovation and influenza, including in 2014 receiving a Doctorate in Humane Letters honoris causa from St. Joseph University and the Woman of Innovation award from the Connecticut Technology Council and was elected fellow in the International Society of Vaccines in 2015. Dr. Cox holds a Doctorate from the University of Wageningen, received her MBA with distinction from the University of Nyenrode and the University of Rochester, NY and holds a Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands.
Between 2002 and 2005, Mr. Denver was President of Pall Asia, a subsidiary of Pall Corporation, with responsibility for all Pall Corporation activities in the Asia Pacific region.
Andrew joined Pall in 2002 with the acquisition by Pall Corporation of US Filter's Filtration and Separations business, where he was President. Andrew was appointed President and Chief Operating Officer of the US Filter Filtration and Separations Group in February 1998 after US Filter acquired Memtec Limited. Prior to his position at US Filter, Andrew was President and Chief Operating Officer of Memtec Limited from 1987 to 1997, and prior to that, at Baxter Healthcare Corporation where he was employed for 12 years in a number of positions.
Andrew's last assignment at Baxter Healthcare Corporation was as President of the corporation's US based Medical Devices Division. Andrew is a former Chairman of Universal Biosensors Inc., and a non-executive Director of Cochlear Ltd and Vaxxas Pty Ltd.
Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors. Andrew was appointed as a Director of SpeeDx Pty Ltd in 2009.
Mr. Hoey brings more than 30 years of executive-level experience in business development, licensing, strategic planning, and financing for technology companies. His experience spans the preclinical development of small molecule and biologic therapeutics, molecular diagnostic assays and platforms, and analytical instrumentation. David has completed over $400 million in corporate partnering transactions and equity financings in the United States, Europe, and Japan and has secured extensive contracts for US Government sponsored research. Most recently, David served as vice president of business development at PathoGenetix, a Boston-based company pioneering single molecule detection technologies for automated identification and strain-typing of microorganisms for biodefense, clinical, and industrial applications. During his tenure at PathoGenetix, David secured more than $55 million from US Government contracts and corporate strategic alliances, in addition to a series of equity financings. David has been President and CEO and a member of the Board of Directors of Vaxxas since he joined the company in 2012.
Dr. Dean Moss is CEO of UniQuest, Australia's leading university commercialization entity, managing the intellectual property of The University of Queensland.
Dean has more than 30 years' experience in science, academia, business, management and commercialization in Australia, the US and the UK.
He has been managing director or senior business development executive of several health and biotech companies worldwide, including Agen Biomedical, Launch Diagnostics, AMRAD ICT, AMRAD Biotech, and United Drug. Dean established the highly-successful York Medical Technologies as a start-up in the UK in 2004.
He is a board member of several Australian biotechnology companies and was a member of the investment committee of the pre-seed venture funds Uniseed, the Medical Research Commercialization Fund and the New Zealand Government's KiwiNet. Throughout his career, Dean has managed the raising of more than $100M in venture capital investment.
He sits on the NHMRC Health Innovation Advisory Committee and is Chair of the Go8 Innovation and Commercialization Group. In 2018, Dr. Moss was awarded the title of Adjunct Professor in the Office of the UQ's Deputy Vice-Chancellor (Research).
Dr. Stephen Thompson is a founding partner of Brandon Capital Partners. Before moving to Australia, Stephen was a Director of Apax Partners based in London. Previously, he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California.
Stephen is also currently a director of Amplificare, OncoRes Medical and Respirion Pharmaceuticals. He is a former director of Elastagen, (acquired by Allergan in 2018) and Longas Technologies (acquired 2021).
Stephen has a Bachelor of Science (Honours) from Chelsea College London, a PhD in Immunology from Kings College London and an MBA, specializing in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors and a former director of the Australian Investment Council (AIC).
Peter Gammell joined the Board of Directors of OneVentures in January 2018, and the Board of Vaxxas, a OneVentures investee company, in 2022.
Currently, he is also the Executive Chairman of Invictus Ventures and Non-Executive Chairman of Octet Finance. Prior to this role he was Chief Executive Officer of Seven Group Holdings and Deputy Chairman of Australian Capital Equity (ACE), the Western Australian based holding company associated with Mr Kerry Stokes, which is now one of Australia's largest private companies, which Peter was the Managing Director of for 21 years.
Peter has served as a Director of Seven Network, RM Williams, National Hire, Consolidated Media Holdings and was the Chairman of Coates Hire. He led the creation of the Seven Media Group, a joint venture between Seven Network Limited and the private equity firm Kohlberg Kravis Roberts & Co. in 2006.
In June 2010 Mr Gammell was appointed the Chief Executive Officer of Seven Group Holdings Limited, a public company listed on the Australian Stock Exchange which was formed as a result of the merger of Seven Network Limited and WesTrac Holdings.
During Peter's career he has been instrumental in acquiring and building multi-billion dollar enterprises with in excess of $10 billion of mergers and acquisitions.
Mr Gammell is a member of the Institute of Chartered Accountants of Scotland and holds a Bachelor of Science degree from the University of Edinburgh.